Welcome to Helix Talk, a podcast presented by the Rosalind Franklin University College of Pharmacy.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date

and improve your pharmacy knowledge. This podcast contains general information for educational purposes only. This is

not professional advice and should not be used in lieu of obtaining advice from a qualified

health care provider. And now, on to the show. Welcome to episode 27 of Helix Talk. I'm

your co-host Dr. Kane. I'm Dr. Schumann. And I'm Dr. Patel. And we're resuming our previous

episode, episode 26, where we're reviewing our top drugs or drug classes in the past 20 years.

To recap, my drug of choice was sylidnithil or Viagra. Mine was Fulmax or Tamselosin. And mine was

the new TNF inhibitors, particularly Hamira or Adalimumam.

And today what we're doing is we're completing this off with our runner-up, if you will.

So numbers four or five and six of our most pivotal drug classes in the past 20 years.

Dr. Schumann, you want to kick us off?

Oh, you all kick it off and I'm going to start right off the bed,

is I cheated a slight bit in that one of mine was approved initially in 1993,

but since it came out at an extended release in 1997, I believe, 97,

and then the other agents have come out within the class all the way to 2013, I think it gets a pass.

So if you just allow me that little bit of flexibility, mine's going to be the SNRIs or the

serotonin, norophenaphrin reuptake inhibitors. A class near and dear to my heart in the

mostly in the psychiatric world, but we can see them used in other places.

They sound very much like the SSRIs. So what is the difference here?

All right, so the difference is we went back historically all the way to the tricyclics

antidepressants of the monomene oxidase inhibitors, and we have these very large, almost

...